De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

iBio Beheer

Beheer criteriumcontroles 3/4

De CEO iBio's is Martin Brenner, benoemd in Jan2021, heeft een ambtstermijn van 3.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.07M, bestaande uit 42.8% salaris en 57.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.075% van de aandelen van het bedrijf, ter waarde $ 14.34K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.1 jaar en 7 jaar.

Belangrijke informatie

Martin Brenner

Algemeen directeur

US$1.1m

Totale compensatie

Percentage CEO-salaris	42.8%
Dienstverband CEO	3.8yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	2.1yrs
Gemiddelde ambtstermijn bestuur	7yrs

Recente managementupdates

Recent updates

iBio's (NYSEMKT:IBIO) Wonderful 324% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07

Analyse CEO-vergoeding

Hoe is Martin Brenner's beloning veranderd ten opzichte van iBio's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$15m
Mar 31 2024	n/a	n/a	-US$17m
Dec 31 2023	n/a	n/a	-US$21m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	US$1m	US$458k	-US$29m
Mar 31 2023	n/a	n/a	-US$35m
Dec 31 2022	n/a	n/a	-US$35m
Sep 30 2022	n/a	n/a	-US$32m
Jun 30 2022	US$1m	US$405k	-US$30m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	n/a	n/a	-US$20m
Sep 30 2021	n/a	n/a	-US$21m
Jun 30 2021	US$1m	US$178k	-US$23m

Compensatie versus markt: De totale vergoeding ($USD 1.07M ) Martin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 667.78K ).

Compensatie versus inkomsten: De vergoeding van Martin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Martin Brenner (54 yo)

3.8yrs

Tenure

US$1,069,174

Compensatie

Dr. Martin B. Brenner DVM., Ph D., is Chief Executive Officer of iBio, Inc. from June 27, 2023 and serves as its Director since June 01, 2024. Dr. Brenner was Interim CEO of iBio, Inc. from January 20, 202...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Martin Brenner	CEO, Chief Scientific Officer & Director	3.8yrs	US$1.07m	0.075% $ 14.6k
Felipe Duran	Chief Financial Officer	1.7yrs	US$1.23m	0.014% $ 2.8k
Marc Banjak	Chief Legal Officer	2.6yrs	geen gegevens	0.022% $ 4.2k
Kristi Sarno	Senior VP of Business Development	less than a year	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van IBIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Martin Brenner	CEO, Chief Scientific Officer & Director	less than a year	US$1.07m	0.075% $ 14.6k
Robert Erwin	Member of Scientific Advisory Board	3.8yrs	US$291.75k	geen gegevens
William Clark	Independent Chairman	3.2yrs	US$73.01k	0.0042% $ 818.0
Gary Sender	Lead Independent Director	4yrs	US$71.41k	0.0048% $ 944.8
Vidadi Yusibov	Member of Scientific Advisory Board	20.1yrs	geen gegevens	geen gegevens
James Hill	Independent Director	16.2yrs	US$55.00k	0.0046% $ 892.1
Timothy Blackwell	Member of Clinical Advisory Board	10.3yrs	geen gegevens	geen gegevens
Richard Silver	Member of Clinical Advisory Board	10.3yrs	geen gegevens	geen gegevens
J. Huggins	Member of Clinical Advisory Board	10.3yrs	geen gegevens	geen gegevens
Thomas Medsger	Member of Clinical Advisory Board	10.1yrs	geen gegevens	geen gegevens
Evert Schimmelpennink	Independent Director	3.3yrs	US$57.50k	0.0043% $ 845.3
Alexandra Kropotova	Independent Director	4yrs	US$52.50k	0.0048% $ 944.8

7.0yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IBIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).

iBio Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

iBio, Inc. Announces the Appointment of Kristi Sarno as Senior Vice President of Business Development

iBio, Inc., Annual General Meeting, Nov 27, 2023

iBio, Inc. Appoints Dr. Martin Brenner as CEO

iBio, Inc. Appoints Felipe Duran as Interim Chief Financial Officer, Effective as of February 13, 2023

iBio, Inc. Announces Resignation of Robert Lutz, the Chief Financial and Business Officer as an Executive Officer, Effective February 10, 2023

High number of new and inexperienced directors

Recent updates

iBio, Inc. Announces the Appointment of Kristi Sarno as Senior Vice President of Business Development

Texas A&M University System Board of Regents acquired Manufacturing facility located in Bryan, Texas of iBio, Inc. (NYSEAM:IBIO) for $8.5 million.

New major risk - Financial position

iBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC

iBio, Inc. announced that it expects to receive $15.068742 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors

New major risk - Financial position

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $4.780385 million.

New major risk - Financial position

iBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx

iBio, Inc., Annual General Meeting, Nov 27, 2023

New minor risk - Insider selling

New major risk - Market cap size

iBio, Inc. Appoints Dr. Martin Brenner as CEO

iBio, Inc. Announces the Expansion of Its AI-Powered Technology Stack with the Launch of EngageTx

Third quarter 2023 earnings released: US$0.48 loss per share (vs US$1.42 loss in 3Q 2022)

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

First half 2023 earnings released: US$1.93 loss per share (vs US$1.97 loss in 1H 2022)

iBio, Inc. Appoints Felipe Duran as Interim Chief Financial Officer, Effective as of February 13, 2023

iBio, Inc. Announces Resignation of Robert Lutz, the Chief Financial and Business Officer as an Executive Officer, Effective February 10, 2023

High number of new and inexperienced directors

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

iBio, Inc. to Showcase the RubrYc Discovery Engine During Poster Presentations At Antibody Engineering & Therapeutics Conference 2022

iBio, Inc. Announces Executive Changes

iBio, Inc. Announces the Resignation of Thomas F. Isett as a Member of the Board

iBio, Inc. Appoints William D. (Chip) Clark as Chairman

iBio, Inc., Annual General Meeting, Dec 08, 2022

iBio, Inc. Files a Provisional Patent with the United States Patent and Trademark Office Title 'Epidermal Growth Factor Receptor Variant III Antibodies'

iBio, Inc. announced delayed annual 10-K filing

iBio, Inc. to Report Q4, 2022 Results on Sep 27, 2022

iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate

Consensus forecasts updated

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

iBio, Inc. to Report Q3, 2022 Results on May 12, 2022

Price target decreased to US$1.75

Consensus revenue estimates fall by 52%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

iBio, Inc. to Report Q2, 2022 Results on Feb 14, 2022

iBio, Inc. Shares an Update on Its Lead COVID-19 Vaccine Program, IBIO-202

iBio, Inc Announces Update for its Lead COVID-19 Vaccine Program, IBIO-202, in Light of the Emergence of the Omicron (B.1.1.529) Variant of SARS-CoV-2

Price target decreased to US$2.25

First quarter 2022 earnings released: US$0.041 loss per share (vs US$0.047 loss in 1Q 2021)

iBio, Inc. Provides Revenue Guidance for the First Half, Second Half and Full Year of Fiscal 2022

Full year 2021 earnings released: US$0.12 loss per share (vs US$0.61 loss in FY 2020)

Independent Director Seymour Flug has left the company

High number of new directors

iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

iBio, Inc.(NYSEAM:IBIO) dropped from Russell Microcap Growth Index

Third quarter 2021 earnings released: US$0.036 loss per share (vs US$0.059 loss in 3Q 2020)

iBio, Inc. Reports Successful Covid-19 Vaccine Toxicology Study Results and Announces Next-Gen Covid-19 Vaccine Program

iBio, Inc. and Fraunhofer USA, Inc. Concludes Litigation

Revenue beats expectations

Second quarter 2021 earnings released: US$0.043 loss per share (vs US$0.69 loss in 2Q 2020)

iBio, Inc. Appoints Robert M. Lutz as Chief Financial & Business Officer, Effective March 4, 2021

iBio, Inc. to Report Q2, 2021 Results on Feb 16, 2021

New 90-day high: US$2.17

iBio's (NYSEMKT:IBIO) Wonderful 324% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: US$1.08

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

Price target lowered to US$2.00

iBio, Inc. Announces Resignation of Robert L. Erwin as President

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $32.493644 million.

iBio to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

iBio, Inc. to Report Q1, 2021 Results on Nov 16, 2020

iBio, Inc. Appoints Randy J. Maddux as Chief Operating Officer, Effective December 1, 2020

iBio, Inc. Announces Appointment of Members to Committees

iBio, Inc. Appoints Gary Sender to Its Board of Directors

iBio, Inc. Announces the Appointment of Linda Armstrong to Board of Directors

iBio Regains Compliance with NYSE American Continued Listing Standards

iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System